Booster shot

11 September 2017 By Neil Unmack

Installing former Lundbeck boss Kare Schultz as CEO has given the Israeli drugmaker’s shares a shot in the arm. The new boss now needs to cut costs, and manage the group’s $35 bln debt pile. That’s hard given Teva’s challenges, and a tough market for generic drugs.

This content is for Subscribers only

To access full content you must be a subscriber. Please use the following link to request a trial.


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)